Silbert CK, Palmer ME, Humphries DE, Silbert JE: Production of [3H]hexosamine-labeled proteoglycans by cultures of normal and diabetic skin fibroblasts: dilution of exogenous [3H]glucosamine by endogenous hexosamine from glucose and other sources
Without RCT data on semaglutide for the management of BAD, it is difficult to evaluate its safety and efficacy compared with other BAD therapeutics, but the abovementioned case underscores that newer, longer-acting, and more potent GLP-1RAs not necessarily provide better treatment results in BAD as compared with older, shorter-acting, and less potent GLP-1RAs such as liraglutide
Gebicka, L
So, so many questions, and thank you so much for being here
Insurance coverage depends on medical necessity documentation - most plans cover treatment for FDA-approved indications but may require prior authorization
Carmeliet P